The Latest Breaking News from ANAB

This Biotech Stock Has More Than Tripled in 2025, but Red Flags Are Waving

AnaptysBio (ANAB) has surged 227% over the past year, hitting a 5-year high. Shares have strong technical momentum and a 100% “Buy” opinion from Barchart. Analyst sentiment remains bullish, but Wall Street thinks earnings and revenue will decline next year. More than 30% of the float is sold short, creating...

Barchart · Dec 19, 2025

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE:GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ:ANAB) in the Delaware Chancery Court.

Benzinga · Nov 21, 2025

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

AnaptysBio Inc. (NASDAQ:ANAB) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis.

Benzinga · Nov 10, 2025

AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne 

Benzinga · Mar 15, 2022

AnaptysBio's Return On Capital Employed Insights

AnaptysBio (NASDAQ:ANAB) brought in sales totaling $1.01 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 388.12%, resulting in a loss of $32.54 million.

Benzinga · Mar 10, 2022

Recap: AnaptysBio Q4 Earnings

  AnaptysBio (NASDAQ:ANAB) reported its Q4 earnings results on Monday, March 7, 2022 at 09:00 AM. Here's what investors need to know about the announcement. Earnings AnaptysBio reported an EPS of $-1.18.

Benzinga · Mar 7, 2022

ANAB Launches Cannabis Accreditation Program, Provides Quality Assurance To Marijuana Industry

ANSI National Accreditation Board (ANAB), a wholly-owned subsidiary of the American National Standards Institute, has announced the formal launch of its new Cannabis Certificate Accreditation Program (C-CAP).

Benzinga · Jan 31, 2022